Selected Grants
Pathogen-Inactivated Platelets Entering Routine use (PIPER): A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
Clinical TrialPrincipal Investigator · Awarded by Cerus Corporation · 2017 - 2020External Relationships
- Cerus Corporation
- Gilead Sciences, Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.